Meningioma

Current Neurology and Neuroscience Reports

Volumn 13, Issue 4, 2013, Pages

  Fathi, Ali Reza ^a   Roelcke, Ulrich ^a,b  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Benign brain tumor; Chemotherapy; Diagnosis; Imaging; Meningioma; Molecular genetics; Neurofibromatosis; Neurosurgery; Pathology; Radiation therapy; Radiosurgery; Skull base; Somatostatin receptors; Surgery; Targeted therapy

Indexed keywords

ERLOTINIB; ETOPOSIDE; GEFITINIB; HYDROXYUREA; IMATINIB; LUTETIUM 177; MIFEPRISTONE; OCTREOTIDE; PASIREOTIDE; TAMOXIFEN; TEMOZOLOMIDE; VASCULOTROPIN; YTTRIUM 90;

ARTICLE; BRAIN ANGIOGRAPHY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; MENINGIOMA; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WORLD HEALTH ORGANIZATION;

EID: 84874641106     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0337-4     Document Type: Article

References (81)

1. Kotecha RS, Pascoe EM, Rushing E.J., Rorke-Adams LB, Zwerdling T, Gao X., et al. Meningiomas in children and adolescents: A meta-analysis of individual patient data. Lancet Oncol. 2011; 12(13): 1229-39. Comprehensive review on epidemiologic and outcome data for meningiomas in children and adults.
2. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010; 99(3): 307-14.
3. Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011; 114(5): 1250-6.
4. Nakasu S, Hirano A, Shimura T., Llena JF. (Pubitemid 17049781)
5. Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N., Vick NA. Growth rate of non-operated meningiomas. J Neurol. 2008; 255(6): 891-5.
6. Greenberg M. Handbook of Neurosurgery. 6th ed. New York: Thieme; 2006.
7. Louis DN, Ohgaki H, Wiestler O.D., Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2): 97-109. (Pubitemid 47103521)
8. Artlich A, Schmidt D. Immunohistochemical profile of meningiomas and their histological subtypes. Hum Pathol. 1990; 21(8): 843-9. (Pubitemid 20250569)
9. Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol. 2009; 24(12): 1526-35.
10. Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett. 2012; 586(10): 1403-8.
11. Wang X, Gong Y, Wang D., Xie Q, Zheng M, Zhou Y., et al. Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and egfl6 over-expression in benign meningioma tissue and serum. PLoS One. 2012; 7(12): e52707.
12. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol. 2010; 99(3): 315-24.
13. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010; 99(3): 379-91.
14. Gabeau-Lacet D., Aghi M, Betensky R.A., Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg. 2009; 111(3): 464-71.
15. Pravdenkova S, Al-Mefty O, Sawyer J., Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg. 2006; 105(2): 163-73.
16. Hasseleid BF, Meling TR, Ronning P, Scheie D., Helseth E. Surgery for convexity meningioma: Simpson Grade I resection as the goal. J Neurosurg. 2012; 117(6): 999-1006.
17. Black PM, Morokoff AP, Zauberman J. Surgery for extra-axial tumors of the cerebral convexity and midline. Neurosurgery. 2008; 62(6 Suppl 3): 1115-21.discussion 21-3
18. Yang SY, Park CK, Park S.H., Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008; 79(5): 574-80. (Pubitemid 351571878)
19. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. a multivariate analysis. Surg Neurol. 1986; 26(5): 461-9. (Pubitemid 16006137)
20. Tseng KY, Chung MH, Sytwu H.K., Lee HM, Chen KY, Chang C, et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol. 2010; 100(2): 217-23. Osteopontin represents an integrin-binding protein and constitutes a prognostic factor which relates to progression-free survival within the histopathologic 'en-tity' of WHO I meningiomas.
21. Saloner D, Uzelac A, Hetts S., Martin A, Dillon W. Modern meningioma imaging techniques. J Neurooncol. 2010; 99(3): 333-40.
22. Omay SB, Barnett GH. Surgical navigation for meningioma surgery. J Neurooncol. 2010; 99(3): 357-64.
23. Hoover JM, Morris JM, Meyer FB. Use of preoperative magnetic resonance imaging T1 and T2 sequences to determine intraoperative meningioma consistency. Surg Neurol Int. 2011; 2: 142.
24. Osawa T, Tosaka M, Nagaishi M., Yoshimoto Y Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol. 2012; 111: 49-57.
25. Regelsberger J, Hagel C, Emami P., Ries T, Heese O, Westphal M. Secretory meningiomas: A benign subgroup causing life-threatening complications. Neuro Oncol. 2009; 11(6): 819-24.
26. Qi ST, Liu Y, Pan J., Chotai S, Fang LX. A radiopathological classification of dural tail sign of meningiomas. J Neurosurg. 2012; 117(4): 645-53.
27. Jolapara M, Kesavadas C, Radhakrishnan V.V., Thomas B., Gupta AK, Bodhey N, et al. Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol. 2010; 37(5): 277-83.
28. Chang V, Narang J, Schultz L., Issawi A, Jain R, Rock J., et al. Computeraided volumetric analysis as a sensitive tool for the management of incidental meningiomas. Acta Neurochir (Wien). 2012; 154(4): 589-97. discussion 97.
29. Fathi AR, Marbacher S, Lukes A. Cost-effective patient-specific intraoperative molded cranioplasty. J Craniofac Surg. 2008; 19(3): 777-81. (Pubitemid 351786504)
30. Rubin G, Herscovici Z, Laviv Y., Jackson S, Rappaport ZH. Outcome of untreated meningiomas. Isr Med Assoc J. 2011; 13(3): 157-60.
31. Quinones-Hinojosa A., Kaprealian T, Chaichana K.L., Sanai N., Parsa AT, Berger MS, et al. Pre-operative factors affecting resect-ability of giant intracranial meningiomas. Can J Neurol Sci. 2009; 36(5): 623-30.
32. Carli DF, Sluzewski M, Beute G.N., van Rooij WJ. Complications of particle embolization of meningiomas: frequency, risk factors, and outcome. AJNR Am J Neuroradiol. 2010; 31(1): 152-4.
33. Afshar-Oromieh A., Giesel FL, Linhart H.G., Haberkorn U., Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012; 39(9): 1409-15.
34. Gehler B, Paulsen F, Oksuz M.O., Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009; 4: 56.
35. Thorwarth D, Muller AC, Pfannenberg C, Beyer T. Combined PET/MR imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients. Recent Results Cancer Res. 2012; 194: 425-39.
36. Sughrue ME, Rutkowski MJ, Aranda D, Barani I.J., McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neuro-surg. 2010; 113(5): 1036-42.
37. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neuro-surg. 2006; 105(4): 538-43. (Pubitemid 44525882)
38. Chamoun R, Krisht KM, Couldwell WT. Incidental meningiomas. Neurosurg Focus. 2011; 31(6): e19.
39. Dirks MS, Butman JA, Kim H.J., Wu T., Morgan K, Tran AP, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012; 117(1): 109-17.
40. Goutagny S, Bah AB, Henin D, Parfait B., Grayeli AB, Sterkers O, et al. Longterm follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol. 2012; 14(8): 1090-6.
41. Adachi K, Kawase T, Yoshida K., Yazaki T, Onozuka S. ABC Surgical Risk Scale for skull base meningioma: A new scoring system for predicting the extent of tumor removal and neurological outcome. Clinical article. J Neurosurg. 2009; 111(5): 1053-61.
42. Gerlach R, Raabe A, Scharrer I., Meixensberger J, Seifert V. Postoperative hematoma after surgery for intracranial meningiomas: causes, avoidable risk factors and clinical outcome. Neurol Res. 2004; 26(1): 61-6. (Pubitemid 38174389)
43. Strassner C, Buhl R, Mehdorn HM. Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res. 2009; 31(5): 478-82. With better operating modalities and addition-al treatment with radiation and gamma knife, the mortality decreased significantly from 12 % to 3 % and the outcome of the patients is still improving, so that even elderly patients can undergo surgical treatment with minor risks.
44. Al-Mefty O., Holoubi A, Rifai A., Fox JL. Microsurgical removal of suprasellar meningiomas. Neurosurgery. 1985; 16(3): 364-72. (Pubitemid 15110003)
45. Kim EH, Cho JM, Chang J.H., Kim SH, Lee KS. Application of intraoperative indocyanine green videoangiography to brain tumor surgery. Acta Neurochir (Wien). 2011; 153(7): 1487-95.discussion 94-5
46. Coluccia D, Fandino J, Fujioka M., Cordovi S, Muroi C, Landolt H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien). 2010; 152(10): 1711-9.
47. Bekelis K, Valdes PA, Erkmen K, Leblond F., Kim A, Wilson BC, et al. Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg Focus. 2011; 30(5): e8.
48. Soleman J, Fathi AR, Marbacher S, Fandino J. The role of intraoperative magnetic resonance imaging in complex meningioma surgery magnetic resonance imaging. Magnetic Resonance Imaging. 2012; In Press [accepted].
49. Solheim O, Selbekk T, Lindseth F., Unsgard G Navigated resection of giant intracranial meningiomas based on intraoperative 3D ultrasound. Acta Neurochir (Wien). 2009; 151(9): 1143-51.
50. Marbacher S, Coluccia D, Fathi A.R., Andereggen L., Beck J, Fandino J. Intraoperative patient-specific reconstruction of partial bone flap defects after convexity meningioma resection. World Neurosurg. 2013; 79(1): 124-30.
51. Dehdashti AR, Ganna A, Witterick I., Gentili F. Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. Neurosurgery. 2009; 64(4): 677-87.discussion 87-9
52. Fatemi N, Dusick JR, de Paiva Neto MA, Malkasian D, Kelly DF. Endonasal versus supraorbital keyhole removal of craniopharyngiomas and tuberculum sellae meningiomas. Neurosurgery. 2009; 64(5 Suppl 2): 269-84.discussion 84-6
53. Komotar RJ, Starke RM, Raper D.M., Anand VK, Schwartz TH. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012; 77(5-6): 713-24.
54. Schroeder HW, Hickmann AK, Baldauf J. Endoscope-assisted microsurgical resection of skull base meningiomas. Neurosurg Rev. 2011; 34(4): 441-55.
55. Bledsoe JM, Link MJ, Stafford S.L., Park PJ, Pollock BE. Radiosurgery for large-volume (>10 cm3) benign meningiomas. J Neurosurg. 2010; 112(5): 951-6.
56. Bloch O, Kaur G, Jian B.J., Parsa AT, Barani IJ. Stereotactic radiosurgery for benign meningiomas. J Neurooncol. 2012; 107(1): 13-20.
57. Flannery TJ, Kano H, Lunsford L.D., Sirin S., Tormenti M, Niranjan A, et al. Long-term control of petroclival meningiomas through radiosurgery. J Neurosurg. 2010; 112(5): 957-64.
58. Astner ST, Theodorou M, Dobrei-Ciuchendea M, Auer F., Kopp C, Molls M, et al. Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas. Strahlenther Onkol. 2010; 186(8): 423-9.
59. Kondziolka D, Madhok R, Lunsford L.D., Mathieu D., Martin JJ, Niranjan A, et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg. 2009; 111(3): 458-63.
60. Kondziolka D, Mathieu D, Lunsford L.D., Martin JJ, Madhok R, Niranjan A, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008; 62(1): 53-8.discussion 8-60 (Pubitemid 351640243)
61. Stessin AM, Schwartz A, Judanin G., Pannullo SC, Boockvar JA, Schwartz TH, et al. Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. J Neurosurg. 2012; 117(4): 669-75.
62. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S. Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol. 2010; 98(3): 367-72.
63. Attia A, Chan MD, Mott R.T., Russell GB, Seif D, Daniel Bourland J, et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurooncol. 2012; 108(1): 179-85.
64. Santacroce A, Walier M, Regis J., Liscak R, Motti E, Lindquist C., et al. Longterm tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012; 70(1): 32-9. discussion 9. One of the largest series with gamma knife treatment of benign meningiomas (5300 treated tumors) reported on 5- and 10-year progression-free survival rates of 95.2 % and 88.6%, respectively.
65. Henze M, Dimitrakopoulou-Strauss A, Mlker-Zabel S, Schuhmacher J, Strauss L.G., Doll J., et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005; 46(5): 763-9.
66. Schulz S, Pauli SU, Handel M, Dietzmann K., Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000; 6(5): 1865-74. (Pubitemid 30305083)
67. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008; 13(1): 822-40.
68. Bruns C, Lewis I, Briner U., Meno-Tetang G, Weckbecker G. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002; 146(5): 707-16. (Pubitemid 34552506)
69. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E., et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009; 36(9): 1407-16.
70. 177Lu-DOTATOC in newly diagnosed meningioma WHO I.
71. Mason WP, Gentili F, Macdonald D.R., Hariharan S., Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002; 97(2): 341-6. (Pubitemid 34827334)
72. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. JNeurooncol. 2012; 107(2): 315-21.
73. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatmentresistant recurrent meningioma. Neurology. 2004; 62(7): 1210-2.
74. Goodwin JW, Crowley J, Eyre H.J., Stafford B., Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. J Neurooncol. 1993; 15(1): 75-7. (Pubitemid 23049702)
75. Grunberg SM, Weiss MH, Russell C.A., Spitz IM, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006; 24(8): 727-33. (Pubitemid 44949876)
76. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69(10): 969-73. (Pubitemid 47366049)
77. Johnson DR, Kimmel DW, Burch P.A., Cascino TL, Giannini C, Wu W, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal heman-giopericytoma. Neuro Oncol. 2011; 13(5): 530-5.
78. Nayak L, Iwamoto FM, Rudnick J.D., Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012; 109(1): 187-93.
79. Lou E, Sumrall AL, Turner S, Peters K.B., Desjardins A., Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: A retrospective series. J Neurooncol. 2012; 109(1): 63-70.
80. Horak P, Wohrer A, Hassler M., Hainfellner J, Preusser M, Marosi C. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: A retrospective analysis. J Neurooncol. 2012; 109(2): 323-30.
81. Norden AD, Raizer JJ, Abrey L.E., Lamborn KR, Lassman AB, Chang SM, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010; 96(2): 211-7.